Daiichi Sankyo has patented a method for efficiently producing compounds with a spirooxindole skeleton, including those with antitumor activity. The process involves an asymmetric catalyst to obtain optically active tricyclic dispiroindole skeletons through a 1,3-dipolar cycloaddition reaction. GlobalData’s report on Daiichi Sankyo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Daiichi Sankyo, Cancer treatment biomarkers was a key innovation area identified from patents. Daiichi Sankyo's grant share as of January 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11884678B2) discloses a method for producing a compound of formula (XXII) or its salt by hydrolyzing a specific compound (XIX). The method involves utilizing a chiral ligand with an (R) stereoconfiguration, such as (R)-BINAP, and a Lewis acid like CuOAc. Additionally, the compound produced in this method may have R53 as ethyl.
The patent also claims a method for producing a compound with formula (XXII) using a chiral ligand with an (R) stereoconfiguration, specifically mentioning (R)-BINAP, and a Lewis acid like CuOAc. The method further specifies R53 as ethyl. These claims highlight a specific process for synthesizing a compound of interest, emphasizing the importance of the chiral ligand's stereoconfiguration and the choice of Lewis acid in the production process. Such methods are crucial in the field of chemical synthesis for creating compounds with desired properties and applications.
To know more about GlobalData’s detailed insights on Daiichi Sankyo, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.